Detect early cognitive decline Parkinsons
- Trial ID
- NCT05025254
- Official Title
- Deep Cognitive Endophenotyping of Parkinson's Disease: A Platform Development and Pilot Study
- Goal
- Detect early cognitive decline Parkinsons
- Status
- RECRUITING
- Sponsor
- McGill University
- Study Type
- OBSERVATIONAL
- Enrollment
- 1000 participants
- Conditions
- Parkinson Disease
- Interventions
- Neurocognitive testing
Plain-Language Summary
The goal is to create a detailed cognitive fingerprint to better identify and track the thinking and memory changes that happen in Parkinson's, and to develop sensitive tools for future research or care. The approach is observational neurocognitive testing, using paper and computer tasks that measure memory, attention, language, and problem solving to detect subtle changes earlier than routine exams; it does not test a drug and does not change your Parkinson's medications. The study is looking for people aged 45 to 90 with Parkinson's diagnosed by a neurologist, plus healthy adults with no neurological illness as controls. People with psychotic spectrum disorders, uncontrolled depression, advanced dementia needing daily help, major stroke, major head injury, or epilepsy treated with anti-seizure medications are not eligible.
Locations
- McGill University Health Centre, Montreal, Quebec, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Neurocognitive testing. The goal is to create a detailed cognitive fingerprint to better identify and track the thinking and memory changes that happen in Parkinson's, and to develop sensitive tools for future research or care. The approach is observational neurocognitive testing, using paper and computer tasks that measure memory, attention, language, and problem solving to detect subtle changes earlier than routine exams; it does not test a drug and does not change your Parkinson's medications. The study is looking for people aged 45 to 90 with Parkinson's diagnosed by a neurologist, plus healthy adults with no neurological illness as controls. People with psychotic spectrum disorders, uncontrolled depression, advanced dementia needing daily help, major stroke, major head injury, or epilepsy treated with anti-seizure medications are not eligible.
- Who can participate?
- Participants must be between 45 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 1 month.